###### Strengths and limitations of this study

-   We will conduct a comprehensive literature search. Several large multicentre RCTs that are not integrated in any meta-analysis to date will be included.

-   This systematic review will systematically evaluate the effects of dexmedetomidine on delirium and mortality in ICU patients.

-   Our findings may provide evidence and guidance for clinical practice.

-   Our results may be limited by heterogeneity due to variations across individual RCTs in patient population, follow-up duration, treatment duration and dosage of dexmedetomidine.

Introduction {#s1}
============

Delirium is an acute brain illness involving changes in consciousness, attention, cognition and perception[@R1] It is very common in critically ill patients[@R2] and is a serious complication because the occurrence of delirium has been associated with higher morbidity, prolonged hospital stay, worse functional recovery and long-term decline in cognitive function.[@R4] Moreover, recent studies demonstrated that delirium was associated with increased short- and long- term mortality in patients admitted to intensive care unit (ICU).[@R7]

Patients in the ICU need sedation to reduce discomfort from care interventions, facilitate mechanical ventilation, prevent accidental removal of instrumentation and reduce oxygen demands.[@R10] For decades, γ-aminobutyric acid (GABA) receptor agonists (including propofol and benzodiazepines) have been standard of care for sedation in the ICU.[@R10] However, emerging studies suggested that these sedatives could increase the prevalence of delirium.[@R12] Although a proportion of sedation-related delirium is rapidly reversible and may not worsen the prognosis of patients,[@R14] sedatives could reduce the prevalence of delirium that are still needed.

Dexmedetomidine, a highly selective α2-adrenoreceptor agonist, has increasingly been used for sedation in ICU patients.[@R15] Dexmedetomidine exerts sedative property via the receptors within the locus ceruleus.[@R16] Recent studies demonstrated that the sedative effects of dexmedetomidine, unlike other sedative agents, were achieved through the modulation of an endogenous sleep-promoting pathway without disruption of sleep architecture.[@R17] Moreover, dexmedetomidine could also provide analgesia via receptors in the spinal cord,[@R16] and attenuate stress response with minimal respiratory depression.[@R20] Because of its unique mechanism of action, dexmedetomidine has been shown to overcome the limitations of the GABA-mimetic sedatives and thus reduce the incidence of delirium[@R21] and improve survival.[@R23]

Several meta-analyses have evaluated the antidelirium effects of dexmedetomidine in ICU patients. Constantin *et al* [@R25] showed that dexmedetomidine-based sedation was associated with decreased incidence of delirium. However, a Cochrane systematic review concluded that dexmedetomidine did not reduce the prevalence of delirium when used for long-term sedation.[@R26] The results of a network meta-analysis also showed no effects of dexmedetomidine on prevention of delirium.[@R27] These findings were so inconsistent that it may become confusing to clinicians in the choice of the best sedative agents for ICU patients. Moreover, previous meta-analyses have not systematically evaluated whether dexmedetomidine could improve survival in ICU patients. Therefore, there is an urgent need to conduct a meta-analysis. Several large multicentre randomised clinical trials (RCTs)[@R28] that are not integrated in any meta-analysis to date will be included. Hopefully, our findings may provide evidence and guidance for clinical practice.

The objective of this systematic review is to evaluate the effects of dexmedetomidine on delirium and mortality during sedation in ICU patients.

Methods and analysis {#s2}
====================

This systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) checklist.[@R34]

Eligibility criteria {#s2a}
--------------------

-   Study designs: this review will include only RCTs. Cluster RCTs and RCTs with cross-over design will be excluded.

-   Participants: adult patients (aged 18 years or older) requiring sedation in the ICU.

-   Interventions: a comparison between dexmedetomidine and placebo or other sedative agents (including benzodiazepines, propofol, opioid and other sedatives) will be included. We will only include studies that initiates infusion of study drugs after ICU admission.

Outcomes {#s2b}
--------

### Primary outcomes {#s2b1}

Incidence of delirium, using a validated diagnostic method.

### Secondary outcomes {#s2b2}

1.  All-cause mortality within 30 days after ICU admission; if mortality was assessed at other follow-up times (eg, ICU mortality, hospital mortality) or the follow-up times was not reported, we arbitrarily consider them as 30 day mortality and conduct subgroup analysis.

2.  Duration of delirium.

3.  Length of ICU stay.

4.  Length of hospital stay.

5.  Duration of mechanical ventilation.

6.  Time to extubation.

7.  ICU costs.

8.  Patients' and family experience during ICU sedation. For example, using the Intensive Care Experience Questionnaire[@R35] for patients; using the Family Satisfaction in the Intensive Care Unit Questionnaire[@R36] for family members.

9.  Safety outcomes.

10. Hypotension.

11. Hypotension with intervention.

12. Bradycardia.

13. Bradycardia with intervention.

14. Hypoxaemia.

15. Hypoxaemia with intervention.

Study search {#s2c}
------------

The following databases will be searched: the Cochrane Central Register of Controlled Trials, PubMed, Embase, ISI Web of Science from inception to 31 December 2018. The search strategies will be developed using Medical Subject Heading terms and corresponding text words and no language restrictions will be imposed. Details of the search strategy for each database are shown in online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}.
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Ongoing studies will be searched on the WHO International Clinical Trials Registry Platform ([www.who.int/ictrp/search/en/](www.who.int/ictrp/search/en/)), International Standard Randomised Controlled Trials Number registry ([www.isrctn.com](www.isrctn.com)), and the clinicaltrials.gov database.

We also handsearched the reference lists of included studies and previously published meta-analyses in relation to this topic for relevant studies

Study selection {#s2d}
---------------

We will include the following studies: (1) the design was an RCT; (2) the study participants were adult patients (aged 18 years or older) requiring sedation in ICU; (3) compared dexmedetomidine and placebo or other sedative agents, and the drugs were infused after ICU admission; (4) reported the incidence of delirium and/or mortality. Citations identified with electronic and manual searches will be saved and deduplicated in EndNote. Two reviewers (RS and SL) will scan the titles and abstracts of these citations independently and in duplicate against the inclusion criteria. The full text of the studies that pass the first eligibility screening will be obtained to make a final decision whether they were eligible for inclusion. All disagreements were resolved by consensus or by a third reviewer (AL). A flow chart of study selection will be detailed in a PRISMA flow chart.[@R37]

Data extraction {#s2e}
---------------

Two reviewers (SL and YZ) independently will extract data from the articles using a predesigned data extraction form, and any disagreement will be resolved by consulting a third reviewer (AL). When a study either overlapped or was a duplicate of another study, we will contact the study authors for clarification and, if confirmed, will use the publication with the more detailed data for this meta-analysis and combined the additional data.

The following information will be extracted:Basic information: title, publication year, name of authors, centres (single-centre, multi-centre), registration identification, funding.Participants: sample size, country/countries, mean age, gender distribution, ICU types (mixed ICU, medical ICU, surgical ICU, coronary care unit (CCU), respiratory care unit, burn unit, other), target sedation range, sedation duration.Interventions: loading dose, maintenance infusion dose, treatment duration.Comparator: placebo or other sedative agents, loading dose, maintenance infusion dose, treatment duration.Outcomes: incidence of delirium, the definition of delirium and the time assessed, duration of delirium, mortality and the follow-up time assessed, length of ICU stay, length of hospital stay, duration of mechanical ventilation, time to extubation, ICU costs and safety outcomes, such as hypotension, bradycardia and hypoxaemia.

Methodological quality appraisal {#s2f}
--------------------------------

The Cochrane risk of bias tool[@R38] will be used to evaluate the methodological quality of included studies. The Cochrane risk of bias tool includes seven domains including sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias, and each domain will be classified as either 'low', 'high' or 'unclear' risk of bias. Two reviewers (RS and SW) will independently perform the methodological quality assessment, with disagreements being resolved by discussion or a third reviewer (AL).

Data synthesis {#s2g}
--------------

Meta-analysis will be performed using Review Manager Software V.5.2. For the outcomes in the present systematic review, dichotomous data and continuous data will be calculated as risk ratios and standardised mean difference with the corresponding 95% CIs, respectively. The statistical heterogeneity among studies will be assessed by the χ^2^ test (statistically significant at p\<0.05)[@R39] and quantified by the I^2^ statistics (25%, 50% and 75% is considered as low, moderate and high heterogeneity, respectively).[@R40] Assuming the existence of variations across individual RCTs in patient population, follow-up duration, treatment duration and dosage of dexmedetomidine, the random-effects model will be used to pool the data. When substantial heterogeneity is detected, we will explore possible explanations in subgroup analyses. If there is not enough available data (less than two studies) for any comparison, we will conduct a narrative, qualitative description instead of a meta-analysis.[@R38]

Continuous data that presented as medians and IQR or ranges will be converted to means and SD as the instruction of Cochrane Handbook.[@R38] The median value will be equivalent to the mean, and the SD will be estimated as 'IQR/1.35' or 'range/4' (small studies, n\<70) or 'range/6' (larger studies, n\>70).[@R41] We will conduct sensitive analysis by excluding these estimated data to evaluate the robustness of results.

Sample size calculation {#s2h}
-----------------------

In a previous meta-analysis,[@R4] the overall incidence of delirium in ICU patients was 31.8%. We assume 20% of the reduction in incidence of delirium as clinically important. With a significance and power set at 0.05 (two-sided) and 80%, respectively, the sample sizes required to detect differences is 1584 patients. With a significance and power set at 0.05 (two-sided) and 90%, the required sample size is 2120 patients.

Subgroup analysis and investigation of heterogeneity {#s2i}
----------------------------------------------------

If there are adequate data, we will perform subgroup analyses for the primary outcomes as follows.

For incidence of delirium and mortality:Age of participants: aged \>60 years or \<60 years.Type of ICU: mixed ICU, medical ICU, surgical ICU, CCU, respiratory care unit, burn unit, others.Target sedation range: deep sedation or light sedation.Sedation duration: short term (\<24 hours) or long term (\>24 hours).Infusion rate of dexmedetomidine: high infusion rate or low infusion rate.Infusion regimen of dexmedetomidine: with loading does or without loading dose.Timing of infusion: at night or at daytime.Comparator: placebo, benzodiazepines, propofol, opioids, other sedatives.

For incidence of delirium: delirium assessment tools used.

For mortality: follow-up duration.

Sensitivity analysis {#s2j}
--------------------

To evaluate whether the results of the systematic review are robust, we will conduct sensitivity analyses for the primary outcomes by excluding studies with small sample sizes, studies of low methodological quality (did not clearly report methods for blinding and allocation concealment) and studies with high percentage of withdrawals (above 10%).[@R42] We will perform sensitive analyses for the continuous outcomes excluding studies reporting data other than mean deviation and SD.

Assessment of reporting biases {#s2k}
------------------------------

For the primary outcomes, if there are 10 or more studies in an analysis, a funnel plot will be drawn to explore the possibility of publication bias.[@R43] Statistically, we will also assess publication bias by Egger's test[@R44] using Stata V.11.0. We will base evidence of asymmetry on p\<0.05.

Summary of findings table {#s2l}
-------------------------

We will assess the quality of evidence for each outcome with Grading of Recommendations Assessment, Development and Evaluation approach.[@R45] We will provide a summary of findings table in five domains (risk of bias, inconsistency, indirectness, imprecision, and publication bias) for each outcome. For each downgrade factor, a judgement of 'no', 'serious (downgrade the quality of evidence by one level)' or 'very serious (downgrade the quality of evidence by two levels)' was assigned. Before rating, we classified all the outcomes as at' high' quality by default, and after rating, each outcome could receive a grade of either' 'high', 'moderate', 'low' or 'very low' quality.

Patient and public involvement {#s2m}
------------------------------

Patients and public were not involved in development of the research question or the design of this study.

Ethics and dissemination {#s2n}
------------------------

The present study is a meta-analysis based on published studies, thus ethical approval is not needed. The systematic review will be conducted and reported according to the PRISMA statement. The results of this meta-analysis will be submitted to a peer reviewed journal for publication.
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